THE NMR STRUCTURE OF THE INHIBITED CATALYTIC DOMAIN OF HUMAN STROMELYSIN-1

被引：132

作者：

GOOLEY, PR ^{[1
]}

OCONNELL, JF ^{[1
]}

MARCY, AI ^{[1
]}

CUCA, GC ^{[1
]}

SALOWE, SP ^{[1
]}

BUSH, BL ^{[1
]}

HERMES, JD ^{[1
]}

ESSER, CK ^{[1
]}

HAGMANN, WK ^{[1
]}

SPRINGER, JP ^{[1
]}

JOHNSON, BA ^{[1
]}

机构：

[1] MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MED CHEM RES,RAHWAY,NJ 07065

来源：

NATURE STRUCTURAL BIOLOGY | 1994年 / 1卷 / 02期

关键词：

D O I：

10.1038/nsb0294-111

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The three-dimensional structure of the catalytic domain of stromelysin-1 complexed with an N-carboxyl alkyl inhibitor has been determined by NMR methods. The global fold consists of three helices, a five stranded beta-sheet and a methionine located in a turn near the catalytic histidines, classifying stromelysin-1 as a metzincin. Stromelysin-1 is unique in having two independent zinc binding sites: a catalytic site and a structural site. The inhibitor binds in an extended conformation. The S1' subsite is a deep hydrophobic pocket, whereas S2' appears shallow and 53' open.

引用

页码：111 / 118

页数：8

共 50 条

[41] Stromelysin-1 regulates adipogenesis during mammary gland involution
Alexander, CM
Selvarajan, S
Mudgett, J
Werb, Z
JOURNAL OF CELL BIOLOGY, 2001, 152 (04): : 693 - 703
[42] Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers
SaarialhoKere, UK
Vaalamo, M
Puolakkainen, P
Airola, K
Parks, WC
KarjalainenLindsberg, ML
AMERICAN JOURNAL OF PATHOLOGY, 1996, 148 (02): : 519 - 526
[43] DISTINCT POPULATIONS OF BASAL KERATINOCYTES EXPRESS STROMELYSIN-1 AND STROMELYSIN-2 IN CHRONIC ULCERS
PARKS, WC
SAARIALHOKERE, U
PENTLAND, AP
WELGUS, HG
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) : 528 - 528
[44] Potent, selective pyrone-based inhibitors of stromelysin-1
Puerta, David T.
Mongan, John
Tran, Ba L.
McCammon, J. Andrew
Cohen, Seth M.
Journal of the American Chemical Society, 2005, 127 (41): : 14148 - 14149
[45] Macrophage cytokine production is defective in stromelysin-1 deficient mice
Warner, RL
McClintock, S
Varani, J
Johnson, KJ
FASEB JOURNAL, 2003, 17 (05): : A1362 - A1362
[46] X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: Implications for inhibitor selectivity
Pavlovsky, AG
Williams, MG
Ye, QZ
Ortwine, DF
Purchase, CF
White, AD
Dhanaraj, V
Roth, BD
Johnson, LL
Hupe, D
Humblet, C
Blundell, TL
PROTEIN SCIENCE, 1999, 8 (07) : 1455 - 1462
[47] The role of stromelysin-1 in stromal-epithelial interactions and cancer
Wiesen, JF
Werb, Z
ENZYME & PROTEIN, 1996, 49 (1-3) : 174 - 181
[48] CLONING AND SEQUENCING OF A CDNA-ENCODING MOUSE STROMELYSIN-1
HAMMANI, K
HENRIET, P
EECKHOUT, Y
GENE, 1992, 120 (02) : 321 - 322
[49] Isolation, characterization, and expression of stromelysin-1 in primary tumors of dogs
Sorensen, KC
Newman, RG
Kitchell, BE
Schaeffer, DJ
Siegel, AM
AMERICAN JOURNAL OF VETERINARY RESEARCH, 2005, 66 (09) : 1526 - 1535
[50] Orally active inhibitors of stromelysin-1 (MMP-3)
Chapman, KT
Durette, PL
Caldwell, CG
Sperow, KM
Niedzwiecki, LM
Harrison, RK
Saphos, C
Christen, AJ
Olszewski, JM
Moore, VL
MacCoss, M
Hagmann, WK
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (07) : 803 - 806

← 1 2 3 4 5 →